Xizang Weixinkang Pharmaceutical Co., Ltd. Class A

Xizang Weixinkang Pharmaceutical Co., Ltd. Class A

SSSE:603676
8.07
CNY
+0.03
(+0.37%)
0.44EPS
20.60P/E
3.96BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
163
0.92
2.42
1.19
1.08
1.73
1.73
1.71
2.48
3.24
3.09
3.01
2.63
2.53
Basic EPS, GAAP
39.5
0.25
0.62
0.32
0.26
0.17
0.13
0.14
0.23
0.41
0.5
0.57
0.54
0.44
Free Cash Flow per Basic Share
-4.14
0.11
0.39
0.22
-0.04
-0.03
0.15
0.19
0.28
0.39
0.4
0.73
0.24
- -
Dividend per Share
- -
0.15
- -
0.16
0.01
0.08
0.05
0.05
0.1
0.16
0.23
0.41
0.38
0.2
Book Value per Share
112.27
136.28
1.12
1.28
2.03
2.12
2.2
2.32
2.45
2.8
3.08
3.18
3.39
3.62
Tangible Book Value per Share
108.19
129.83
1.04
1.19
1.93
2.02
2.09
2.17
2.26
2.66
2.95
3.11
3.31
3.49
Basic Weighted Avg Shares
2
423
182
359
391
432
428
417
417
432
428
432
431
431
Sales/Revenue/Turnover
342
391
440
426
420
746
741
716
1,034
1,399
1,323
1,300
1,136
1,090
Operating Margin (%)
29.31
32.12
27.33
26.14
20.17
7.47
6.04
6.33
9.42
11.95
11
21.73
22.83
19.98
Depreciation Expense
7
9
12
19
19
23
27
31
34
41
49
53
51
- -
Net Income, GAAP
83
107
113
115
102
73
56
58
96
177
214
246
233
190
Effective Tax Rate (%)
19.44
15.23
10.41
9.43
11.98
5.54
15.55
16.08
16.04
2.96
0.84
11
17.89
14.38
Profit Margin (%)
24.23
27.31
25.65
26.95
24.17
9.84
7.51
8.16
9.28
12.65
16.18
18.93
20.5
17.45
Working Capital
100
69
132
175
526
513
533
524
590
727
805
888
941
1,020
LT Debt
- -
- -
- -
- -
- -
- -
- -
4
2
3
4
2
7
3
Total Equity
248
286
403
459
858
898
930
983
1,067
1,221
1,340
1,385
1,476
1,574
Return on Invested Capital (%)
- -
37.82
30.03
23.34
11.82
8.13
5.04
5.19
8.32
13.68
13.43
18.26
16.63
12.34
Return on Capital (%)
- -
36.43
32.75
26.61
15.01
8.3
6.01
6.09
9.31
15.41
16.65
17.99
16.19
12.38
Return on Common Equity (%)
- -
40.9
32.78
26.65
15.42
8.37
6.09
6.11
9.36
15.47
16.71
18.06
16.27
12.42

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
435
435
435
Market Capitalization
4,613
3,503
3,956

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,367
1,389
1,365
Cash, Cash Equivalents & STI
1,053
1,065
1,013
Accounts Receivable, Net
151
155
177
Inventories
58
63
60
Total Current Liabilities
365
384
345
Payables & Accruals
- -
- -
- -
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.74%
8.53%
6.56%
Free Cash Flow
-64.89%
21.91%
-67.7%
Net Income, GAAP
12.24%
35.84%
-5.41%
Sales/Revenue/Turnover
12.88%
11.99%
-12.65%
Total Cash Common Dividend
- -
59.63%
-8.1%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
318
315
361
306
1,300
2025
296
290
- -
273
1,136
2026
322
262
232
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.16
0.18
0.01
0.57
2025
0.2
0.23
- -
0.03
0.54
2026
0.16
0.17
0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.07
0.16
0.17
0.41
2025
0.01
0.17
- -
0.18
0.38
2026
- -
- -
0.01
- -
- -

Company Description

CEO
Yong Zhang
Full Time Employees
763
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 4 Lhasa Xizang Province China 850000
IPO Date
Jul 21, 2017
Business
Tibet Weixinkang Medicine Co., Ltd. engages in the research, development, production, and sale of chemical pharmaceutical preparations and their active pharmaceutical ingredients in China. The company specializes in parenteral nutrition and related products, including multivitamins for injection (12), pediatric multivitamin injection (13), multi-trace element injection, compound electrolyte injection (V), mixed sugar electrolyte injections, potassium magnesium aspartate injection, potassium aspartate injection, iron sucrose injection, injectable acetylcysteine solution for inhalation, compound amino acid injections, antibiotics, and medicines for digestive system and liver diseases; it also provides pharmaceutical marketing services. Founded in 2006 and headquartered in Lhasa, Tibet Autonomous Region, the company operates primarily in the domestic market through a network covering over 3,000 secondary and above-level medical institutions, with 11 to 13 subsidiaries in locations including Beijing, Inner Mongolia, Hainan, Jiangsu, and Hong Kong. Tibet Weixinkang Medicine Co., Ltd., formerly known as Weixinkang Medicine Youxian Gongsi, changed its name in 2015 and listed on the Shanghai Stock Exchange mainboard (603676.SS) in 2017. In recent developments, the company announced a share repurchase program in 2024 for up to CNY 30 million at a price not exceeding CNY 12.12 per share; it received market approval for dopamine hydrochloride injection to treat shock syndromes; and participated in the 89th National Drug Transaction Fair in Wuhan in November 2024, showcasing key parenteral nutrition products amid ongoing R&D expansion with over 40 projects in development, 15 invention patents, and 17 new drug certificates obtained since 2015.